CeMM supports the Seitenwechsel initiative
Seitenwechsel is a spin-off of the MEGA Education Foundation, which promotes innovative educational initiatives in the areas of chance/fairness and business competence/life skills to support Austrian talent. Seitenwechsel is looking for committed and determined teachers who would like to take the opportunity to deepen their experience by working in a company for a year. On the second year, they will bring impulses from their professional…
Season greetings 2020
CeMM continues to be a place where biomedical research excellence goes hand in hand with social responsibility and innovation. With our two new spin-off companies Proxygen and Solgate, with our project on the “Mutational Dynamics of SARS-CoV-2 in Austria”, where CeMM has contributed the majority (>98%) of SARS-CoV-2 virus genomes from Austria to the public database GISAID. With many scientific publications and grants in 2020, resulting from our…
Mutational Dynamics of SARS-CoV-2 in Austria
Following its quest to create the molecular basis for precision medicine and wishing to contribute to fight the COVID-19 pandemia, scientists at CeMM have been sequencing the SARS-CoV-2 genome since March 2020. An interdisciplinary team led by Andreas Bergthaler and Christoph Bock have since obtained more than 1100 samples from Austria, of which 747 resulted in full-length high quality SARS-CoV-2 genomes. These are deposited in the public…
Hematoxylin as a killer of CALR mutant cancer cells: New therapeutic approach for the treatment of primary myelofibrosis
Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and group leader at the Medical University of Vienna, have now identified hematoxylin as a novel CALR…
ERC Consolidator Grant awarded to CeMM Principal Investigator Christoph Bock
We congratulate Christoph Bock, Principal Investigator at CeMM and Guest Professor at the Medical University of Vienna, for receiving a prestigious and well-endowed ERC Consolidator Grant of the European Research Council. ERC Consolidator Grants are awarded to outstanding researchers of any nationality and age, with seven to twelve years of experience after PhD, and a scientific track record showing great promise and achievement. Christoph Bock…
CeMM's spin-off Proxygen enters new partnership with Boehringer Ingelheim to explore molecular glue degraders
CeMM congratulates its spin-off Proxygen on its new collaboration and license agreement with Boehringer Ingelheim. Their new partnership announced today will enable the identification of molecular glue degraders in the aim of degrading cancer drivers that were previously considered undruggable. The collaboration combines Proxygen’s unique molecular glue degrader discovery platform and its expertise in targeted protein degradation with Boehringer…
Thomas Krausgruber awarded the ÖGAI Karl Landsteiner Prize for Basic Research in Immunology 2020
Congratulations to Thomas Krausgruber, Senior Postdoctoral Fellow in Christoph Bock’s Group at CeMM, who has received the Karl Landsteiner Prize for Basic Research in Immunology 2020!Every year the Karl Landsteiner and Eisler-Terramare Foudation Commemoration Trust and the Austrian Society for Allergology and Immunology (ÖGAI) offer a prize of 4,000 € to recognize excellent publications in the field of basic immunology research. The publications…
Cancer in children with rare inborn immune defect: High cure rate if treated early
New research data highlight a marked predisposition to lymphoma, a type of cancer, in children harboring specific gene mutations. A significant fraction of these rare mutations also cause inborn immune defects associated with recurrent infections. Under the leadership of Kaan Boztug, LBI-RUD and CCRI Director and CeMM Adjunct Principal Investigator, and collaborating closely with leading centers across the world, researchers investigated patients…
SLC25A51 regulates the transport of the coenzyme NAD into the mitochondria
Previously poorly characterized gene proved to be an important regulator with potential for the development of new metabolic therapies against ageing and cancer. For their growth, cells need various nutrients and vitamins. So-called solute carriers (SLC), proteins that can transport such substances across the boundaries of cellular membranes, play a central role in metabolism. Scientists in Giulio Superti-Furga’s research group at the CeMM…
Austrian study provides deep insights into transmission and mutation properties of SARS-CoV-2
Learning from past SARS-CoV-2 outbreaks for future pandemic control In the COVID-19 pandemic, 57 million people have already been infected worldwide. In the search for vaccines and therapies, a precise understanding of the virus, its mutations and transmission mechanisms is crucial. A recent study by the research group of Principal Investigator Andreas Bergthaler at the CeMM Research Center for Molecular Medicine of the Austrian Academy of…
Christoph Bock among the world's most highly-cited scientists in 2020
Every year the “Highly Cited Researchers” list provided by Clarivate Analytics recognizes the most influential researchers with highly-cited papers that rank in the top 1% by citation in different scientific fields. This year 39 researchers in the list are working in Austria. Among them, CeMM PI Christoph Bock, who has been included in the cross-field category, highlighting the interdisciplinary nature of his work. Christoph Bock joined CeMM …
Stem cell transplantation: undesirable rejection mechanism identified
In the treatment of leukaemia, stem cell transplantation subsequent to chemotherapy and radiation can often engender severe adverse inflammatory reactions – especially in the skin or in the gut, since these so-called barrier organs are more frequently affected. Up until now, the reason for this was unclear. A MedUni Vienna team led by Georg Stary and Johanna Strobl from MedUni Vienna's Department of Dermatology, the CeMM (Research Center for…
Drug discovery: First highly scalable method developed to monitor protein levels and localizations in cells
Until now, scientists typically studied the changes of proteins and their roles in the cell by using a fluorescent tag to label and follow one protein at a time. This approach limited the number of proteins that could be studied and precluded unbiased discovery approaches. Researchers at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have now developed a highly scalable method which allows for the study of…
CeMM signs framework agreement with the Technology Transfer Fund KHAN-I and its subsidiary wings4innovation GmbH (w4i)
Worth EUR 60 million, the KHAN Technology Transfer Fund I (KHAN-I) has, since July 2019, been financing highly innovative drug discovery projects that open up new therapeutic options for patients, based on ideas and results from Austrian, German and other European research institutions. The projects are developed in line with industry standards together with the research institutions and are commercialized by KHAN-I. The current investment…
Congratulations to CeMM SAB Member Emmanuelle Charpentier for the 2020 Nobel Prize in Chemistry
We congratulate CeMM SAB Member Emmanuelle Charpentier for the 2020 Nobel Prize in Chemistry obtained together with Jennifer A. Doudna for the development of the CRISPR genome editing method. Emmanuelle Charpentier is a French researcher and citizen of Europe recognized as a world-leading expert in regulatory mechanisms underlying processes of infection and immunity in bacterial pathogens. With her groundbreaking findings in the field of…
